RT Journal Article
T1 Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.
A1 Querol, Luis
A1 Rojas-García, Ricard
A1 Diaz-Manera, Jordi
A1 Barcena, Joseba
A1 Pardo, Julio
A1 Ortega-Moreno, Angel
A1 Sedano, Maria Jose
A1 Seró-Ballesteros, Laia
A1 Carvajal, Alejandra
A1 Ortiz, Nicolau
A1 Gallardo, Eduard
A1 Illa, Isabel
K1 Corticoesteroides
K1 Anticuerpos
K1 Anticuerpos monoclonales de origen murino
K1 Autoanticuerpos
K1 Contactina 1
K1 Ensayo de inmunoadsorción enzimática
K1 Humanos
K1 Inmunoglobulina G
K1 Inmunoglobulinas intravenosas
K1 Inmunohistoquímica
K1 Perdida de seguimiento
K1 Polirradiculoneuropatía crónica inflamatoria desmielinizante
K1 Accidente cerebrovascular
AB OBJECTIVETo describe the response to rituximab in patients with treatment-resistant chronic inflammatory demyelinating polyneuropathy (CIDP) with antibodies against paranodal proteins and correlate the response with autoantibody titers.METHODSPatients with CIDP and IgG4 anti-contactin-1 (CNTN1) or anti-neurofascin-155 (NF155) antibodies who were resistant to IV immunoglobulin and corticosteroids were treated with rituximab and followed prospectively. Immunocytochemistry was used to detect anti-CNTN1 and anti-NF155 antibodies and ELISA with human recombinant CNTN1 and NF155 proteins was used to determine antibody titers.RESULTSTwo patients had a marked improvement; another patient improved slightly after 10 years of stable, severe disease; and the fourth patient had an ischemic stroke unrelated to treatment and was lost to follow-up. Autoantibodies decreased in all patients after rituximab treatment.CONCLUSIONSRituximab treatment is an option for patients with CIDP with IgG4 anti-CNTN1/NF155 antibodies who are resistant to conventional therapies.CLASSIFICATION OF EVIDENCEThis study provides Class IV evidence that rituximab is effective for patients with treatment-resistant CIDP with IgG4 anti-CNTN1 or anti-NF155 antibodies.
PB Wolters Kluwer Health/LWW
YR 2015
FD 2015-09-03
LK http://hdl.handle.net/10668/2063
UL http://hdl.handle.net/10668/2063
LA en
NO Querol L, Rojas-García R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015; 2(5):e149
NO Journal Article;
DS RISalud
RD Apr 4, 2025